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Bone formationSclerostin antibody (Scl-Ab) and parathyroid hormone (PTH) are bone-forming agents that have differentmodes
of action on bone, although a study directly comparing their effects has not been conducted. The present study
investigated the comparative quantitative effects of these twobone-forming agents over time on bone at the organ, tis-
sue, and cellular level; speciﬁcally, at the level of the osteoblast (Ob) lineage in adolescentmale and female rats. Brieﬂy,
eight-week old male and female Sprague–Dawley rats were administered either vehicle, Scl-Ab (3 or 50 mg/kg/week
subcutaneously), or human PTH (1–34) (75 μg/kg/day subcutaneously) for 4 or 26weeks. The 50mg/kg Scl-Ab and
the PTH dose were those used in the respective rat lifetime pharmacology studies. Using robust stereological
methods,we compared the effects of these agents speciﬁcally at the level of theOb lineage in vertebrae from female
rats. Using RUNX2 or nestin immunostaining, location, and morphology, the total number of osteoprogenitor
subpopulations, Ob, and lining cells were estimated using the fractionator or proportionator estimators. Density
estimates were also calculated referent to total bone surface, total Ob surface, or total marrow volume.
Scl-Ab generally effected greater increases in cancellous and cortical bonemass than PTH, correlatingwith higher
bone formation rates (BFR) at 4 weeks in the spine and mid-femur without corresponding increases in bone re-
sorption indices. The increases in vertebral BFR/BS at 4 weeks attenuated with continued treatment to a greater
extentwith Scl-Ab thanwith PTH. At 4weeks, both Scl-Ab and PTHeffected equivalent increases in total Obnum-
ber (Ob.N). Ob density on the formative surfaces (Ob.N/Ob.S) remained similar across groups while mineral ap-
position rate (MAR) was signiﬁcantly higher with Scl-Ab at week 4, reﬂecting an increase in individual Ob vigor
relative to vehicle and PTH. After 26weeks, Scl-Abmaintained BFR/BS with fewer Ob and lower Ob.N/Ob.S by in-
creasing the Ob footprint (bone surface area occupied by an Ob) and increasing MAR, compared with PTH. The
lower Ob.N and Ob.N/Ob.S with Scl-Ab at 26 weeks were associated with decreased osteoprogenitor numbers
compared with both vehicle and PTH, an effect not evident at week 4. Osteoprogenitor numbers were generally
positively correlated with Ob.N across groups and timepoints, suggesting dynamic coordination between
the progenitor and Ob populations. The time-dependent reductions in subpopulations of the Ob lineage with
Scl-Ab may be integral to the greater attenuation or self-regulation of bone formation observed at the vertebra,
as PTH required more Ob at the formative site with correlative increased numbers of progenitors compared
with Scl-Ab indicating potentially greater stimulus for progenitor pool proliferation or differentiation.
© 2015 Amgen Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).nded this study.
ve Biology and Safety Sciences,
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This is an open access article under t1. Introduction
Sclerostin antibody (Scl-Ab) and parathyroid hormone (1–34)
(PTH) are bone-forming agents that have different modes of action
on bone. In animals, Scl-Ab increases cancellous and cortical
bone mass predominately through increased modeling-based bonehe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hibitory [1]. This increase in bone formation is effected initially by acti-
vation of bone lining cells (L.Ce) [2], with bone formation maintained
presumably through recruitment of progenitors to the formative sur-
face. In contrast, data in both animals and humans have demonstrated
that intermittent PTH increases cancellous bone mass largely by in-
creasing the remodeling rate with increased bone formation coupled
to increased bone resorption and a net positive bone balance at the
basic multicellular unit level [3,4]. Modeling-based formation has also
been shown to contribute to the initial response to PTH by activation
of L.Ce [5,6], similar to Scl-Ab, but the extent of modeling-based forma-
tion is substantially less than that with Scl-Ab [7,8]. Although both
agents have been demonstrated to increase cortical bone mass, data in
humans suggest that these effects are greater with Scl-Ab [9] at clinical
doses. In addition, intracortical remodeling is not systemically increased
with Scl-Ab in primates [10], unlike the effects of PTH [11,12].
With chronic administration, both agents display attenuation of the
stimulation of bone formation biomarkers but with apparent differ-
ences in temporal patterns, most recently illustrated in a comparative
clinical trial with the Scl-Ab, Romosozumab [9]. Romosozumab effected
transient increases in bone formation markers maximal at 1 month,
returning to or below baseline by 2–9 months, accompanied by a
sustained moderate decrease in resorption marker. In contrast, PTH af-
fected a sustained increase in both formation and resorption markers
over the 12-month treatment period, with maximal increase in forma-
tion markers at 6 months. Although the human skeleton is composed
primarily of cortical bone, cancellous bone contributes a larger surface
area. With similar remodeling rates, cancellous bone would therefore
have a greater contribution to circulating bone biomarkers [13]. Thus
the temporal pattern of changes in bone biomarkers in the comparative
clinical trial suggests that the attenuation of cancellous bone formation
occurs more rapidly with Scl-Ab compared with PTH. The increase in
bone formation occurred in the face of sustained suppression of bone re-
sorption with Scl-Ab, in contrast to sustained increased resorption with
PTH. Animal studies with Scl-Ab indicate that although bone formation
rate attenuates on cancellous surfaces following 6 months of dosing,
endocortical formation ismaintained and resorptionparameters remain
lower on bone surfaces [14]. Although animal studies assessing the
temporal changes associated with chronic PTH treatment are limited
in number and scope, the increases in bone formation in humans also
progressively decrease in cancellous bone following 18 months of
dosing, with the bone-forming effects of PTH on the endocortex
appearing to be temporally coupled with the attenuation in cancellous
bone [15].
Although the comparative clinical trial illustrated differential effects
between the Scl-Ab, romosozumab, and PTH on bone formation
markers and bone mineral density (BMD), a study directly comparing
their effects at the tissue level in cancellous and cortical bone has not
been reported. To this end,we conducted a study comparing the tempo-
ral changes in bone biomarkers, mass, and histomorphometric indices
of bone formation and resorption in cancellous and cortical bone in
male and female rats administered Scl-Ab and PTH. Because these
agents exploit different modes of bone formation to increase bone
mass, we hypothesized that these differences are related to or reﬂected
in differential effects on the osteoblast (Ob) and osteoprogenitor sub-
populations. Therefore, unbiased stereological methods were employed
to obtain estimates of number of Ob, L.Ce, and subpopulations of
osteoprogenitors to explore the potential differential quantitative ef-
fects of these agents on the Ob lineage over time.
2. Methods
2.1. Study design
Male and female Sprague–Dawley (CD®IGS) rats (Charles River Lab-
oratories, Hollister, CA), 148/sex and 8 weeks of age, were divided intofour treatment groups: vehicle (Veh) (n = 20/sex), 3 mg/kg Scl-Ab
(n = 70/sex), 50 mg/kg Scl-Ab (n = 38/sex), and 75 μg/kg human
PTH (1–34) (n = 20). Because the Scl-Ab used in this study,
romosozumab, is immunogenic in rats, Scl-Ab groups were powered
to allow for removal of rats that developed anti-drug antibodies
(ADA) from the study since ADAs can attenuate exposure and pharma-
cological response. Ratswere assigned to treatment groups using a com-
puterized blocking procedure (Pristima Version 6.1.0 Build 45, Xybion
Corp., Morris Plains, NJ) designed to achieve body weight balance with
respect to treatment groups. Scl-Ab (romosozumab, 34.97 mg/mL)
and Veh (55 mM acetate, 13 mM calcium, 6% sucrose, 0.006% polysor-
bate 20, pH 5.2) were administered by subcutaneous (SC) injection
weekly at a dose volume of 1.43 mL/kg. hPTH (1–34) (human parathy-
roid hormone H-483; Bachem, Torrence, CA) was administered daily by
SC injection. PTHwas reconstitutedwith sterile water, aliquoted in vials
and stored at−60 °C until day of use, then diluted to 0.15 mg/mL in
buffer (2% bovine serum albumin, 0.001 N HCl, 0.15 M NaCl) for injec-
tion at a dose volume of 0.5 ml/kg. All dosing was performed in the
morning (prior to approximately noon) within the home animal room
or at the home cage; Veh animals were dosed ﬁrst, followed by the
Scl-Ab and PTH-treated animals.
One cohort of rats was dosed for 4 weeks and the second cohort was
dosed for 26 weeks. Serum was collected from Scl-Ab-treated rats on
study day (D) 29 (week-4 necropsy), D85, and D183 (week-26 necrop-
sy) and analyzed for ADA and serum drug concentrations. ADA assay
and serum drug concentration results were used to conﬁrm adequate
drug exposure throughout the study. All ADA-positive animals were
excluded from the study, with further reductions in ADA-negative ani-
mals when required to reduce the group size for subsequent analyses
to 10/sex/timepoint, based on assigned animal number. Data from
these animalswere used for statistical analysis and study interpretation.
Serumwas collected from theweek 26 cohort on D7, D57, D120, and
D183 (±2 days) for bone biomarker analyses that included N-terminal
type I procollagen (P1NP), osteocalcin (OC), tartrate-resistant acid
phosphatase-5b (TRACP-5b), and collagen type 1 cross-linked C-
telopeptide (CTx). Rats were administered the ﬂuorochrome calcein
green (10 mg/kg SC; Sigma-Aldrich, St. Louis, MO) 10 and 3 days prior
to necropsy for dynamic histomorphometry. Fluorochrome solution
was prepared on each morning of administration in 2% sodium bicar-
bonate in saline at a concentration of 10 mg/mL and ﬁlter sterilized
(0.22 μm syringe ﬁlters).
For euthanasia, animals were anesthetized with isoﬂurane/oxygen
and then exsanguinated. At necropsy, vertebrae T13–L2, left and right
tibia, and left humerus were collected for routine histopathological
evaluation of bone marrow and Ob morphology. Vertebra L3 and left
femur were collected and ﬁxed in 70% ethanol for peripheral quantita-
tive computed tomography (pQCT) analysis. Vertebra L4, right femur
diaphysis, and right femur distal metaphysis were collected, ﬁxed
in 10% neutral buffered formalin (NBF) for 48 h, transferred to 70% eth-
anol and then processed in methyl methacrylate undecalciﬁed for
histomorphometric analyses. L6 vertebral body was collected, ﬁxed in
4% paraformaldehyde (PFA) at 4 °C for 48 h, decalciﬁed in 10% EDTA
with 2% PFA at 4 °C until decalciﬁed, and then processed in parafﬁn
for stereological analyses.
All animalswere cared for in accordance to theGuide for the Care and
Use of Laboratory Animals, 8th Edition[16]. Animals were group-housed
(two per cage) at an Association for Assessment and Accreditation of
Laboratory Animal Care, international-accredited facility in nonsterile,
ventilated, microisolator housing with corn cob bedding. All research
protocols were approved by the Institutional Animal Care and Use Com-
mittee. Animals had ad libitum access to pelleted feed (Rodent Diet
2020X, TekladDiets,Madison,WI) andwater (reverse osmosis puriﬁed)
via an automatic watering system. Animals were maintained on a
12:12 h light:dark cycle in rooms with controlled temperature
(72 °F +/− 2) and humidity (30–70%) and had access to enrichment
opportunities (Nylabones and Rat Retreats or Rat Tunnels).
382 M.S. Ominsky et al. / Bone 81 (2015) 380–3912.2. Serum biomarkers
Whole blood (700 μL) collected from the tail vein was transferred to
a serum separator tube (Microtainer; Becton Dickinson, Franklin Lakes,
NJ). Serum OC was measured using a rat OC single-plex Milliplex kit
(RBN-31K-1OC; Millipore, Billerica, MA), and CTx was measured using
RatLaps (IDS, Gaithersburg, MD). Systemic TRACP-5b and P1NP were
evaluated by enzyme immunoassays (Rat TRACP and Rat/Mouse PINP,
IDS, Gaithersburg, MD). All assays were performed in accordance with
manufacturer protocols.
2.3. pQCT
The left femur was scanned with a Stratec XCT Research M instru-
ment (Norland Medical Systems, Fort Atkinson, WI). The length of the
femur was measured with precision calipers and cross-sectional scans
were performed at two sites: 50% of the length from the distal end for
cortical analyses and 25% of the length from the distal end for
metaphyseal (trabecular) analyses. Measurements were performed
with a voxel size of 0.1 mm using software version 5.40. Cortical bone
was deﬁned and analyzed using contour mode 2 and cortical mode
4, with an outer threshold of 340 mg/cm3. Trabecular bone of the distal
metaphysiswas deﬁned using peelmode 1without further thresholding;
volumetric bone mineral content (vBMC) and volumetric BMD (vBMD)
were determined in the inner 30% of the total area.
The length of the vertebral body was measured with precision cali-
pers from the cranial to the caudal ends, and a cross-sectional scan
was performed at 50% of the length of the body. The Stratec instrument
was used for the vertebral scans as described above for the femur, in-
cluding use of the same voxel size, outer threshold, and peel mode for
collection of data listed for the distal femoral metaphysis.
2.4. Qualitative histopathology
Bones collected for routine histopathology were ﬁxed for 48 h in
NBF, transferred to 70% ethanol, routinely processed in parafﬁn, sec-
tioned at 4 μm, and stained with hematoxylin and eosin. Sections
were evaluated by light microscopy for alterations in bone marrow or
Ob morphology.
2.5. Bone histomorphometry
Undecalciﬁed stained and unstained sections of vertebrae L4 and
femur metaphysis and ground cross sections of mid-shaft femur were
prepared and evaluated/expressed as described previously [17,18].
2.6. Stereological analysis of Ob lineage
Vertebrae L6 from females in all groups at weeks 4 and 26 were
used for estimation of total number of subpopulations of the Ob
lineage. The stereological estimator, the physical fractionator [19],
was used to provide estimates of total number of runt-related
transcription factor 2 (RUNX2)-immunopositive subpopulations in-
cluding Ob, L.Ce, peritrabecular osteoprogenitors (PTb.Op), andmarrow
osteoprogenitors (Ma.Op) in cancellous bone. Number estimates by
these methods are independent of size, shape, distribution, or orienta-
tion. The physical fractionator uses physical disectors (ie, paired consec-
utive thin sections that constitute a three-dimensional [3-D] probe
[volume] in which cells are counted; number is zero-dimensional and
thereforemust be estimated in a 3-Dprobe). The disector countingprin-
ciple uses a unique counting feature of the cell, in this case the nucleus,
and a cell is only countedwhen the nucleus is present in a sampled ﬁeld
in one section of the disector (counting ﬁeld) and not the other (lookup
ﬁeld) [20]. To estimate number of nestin-immunopositivemarrow stro-
mal cells (Ma.St.Ce), the proportionator estimatorwas used [21]. A com-
bination of immunophenotyping,morphology, and locationwas used toclassify cells for estimation (Fig. 1). Further details of immunohisto-
chemical and stereological methods are provided in Supplemental
materials.
2.7. Statistical analyses
All data were analyzed using SAS V9.1.2 in the Windows Vista Pro-
fessional environment. All statistical analyses were conducted by gen-
der and all group and time effects were considered statistically
signiﬁcant at p b 0.05. Dual-energy X-ray absorptiometry, pQCT,
histomorphometry, and stereology endpoints were analyzed using a
two-way analysis of variance (ANOVA) model with cohort (4-week co-
hort vs 26-week cohort), treatment group (Veh, 3 mg/kg Scl-Ab,
50 mg/kg Scl-Ab, and, 75 μg/kg hPTH 1–34), and the two-way interac-
tion between cohort and treatment group as ﬁxed effects. The variance
structure of the model was determined by selecting among four vari-
ance structures: 1. equal variances across treatment groups and equal
variances across cohorts, 2. unequal variances across treatment groups
and equal variances across cohorts, 3. equal variances across treatment
groups and unequal variances across cohorts, and 4. unequal variances
across treatment groups and unequal variances across cohorts using
the AICC criterion (Akaike information criterion with a correction for ﬁ-
nite sample sizes). When there was a convergence issue, the two-way
ANOVA was applied to the ranks of the original data. When ties were
prevalent, Wilcoxon-exact test was also performed in addition to two-
way ANOVA to help evaluate how sensitive the results were to
ties and to achieve robust statistical interpretation of the results. Pair-
wise comparisons (3 mg/kg Scl-Ab vs Veh, 50 mg/kg Scl-Ab vs Veh,
PTH vs Veh, and 50 mg/kg Scl-Ab vs PTH) were performed and a
multivariate-t correction method was used to adjust for multiple
comparisons.
Serum bone biomarker end points collected on week-26 cohorts
were each analyzed using a one-way ANOVA model with treatment
group as a ﬁxed effect for each sample collection time. As described
above, the AICC criterion was used to determine the variance structure
across treatment groups for each ANOVA model. Pairwise comparisons
and multivariate-t correction multiple comparison adjustments were
performed as described above.
3. Results
3.1. Comparative effects of Scl-Ab and PTH on bone biomarkers
In females, an early robust increase in bone formation in response to
Scl-Ab at 50 mg/kg was evident by increases in serum OC and P1NP at
D7 relative to Veh controls (Fig. 2) which attenuated over time but
remained elevated relative to Veh at D182. The increase in bone forma-
tion markers associated with PTH was delayed in females until D57,
with increases in OC generally sustained through D182 (Fig. 2A–B).
CTx was transiently increased at D7 with 50mg/kg Scl-Ab but was sim-
ilar to Veh through the remainder of the timecourse. In contrast, CTx
was increased signiﬁcantly by D57 with PTH and remained elevated at
D182 (Fig. 2C).
Inmales, PTH resulted in the greatest increases in P1NP and OC,with
sustained increases through D182 at a level 2-fold that of the Veh group
and signiﬁcantly greater than the 50 mg/kg Scl-Ab group (Fig. 2D–E). A
slight transient increase in CTx at D7 was observed in males treated
with 3 mg/kg Scl-Ab, also observed in females treated with 50 mg/kg.
Signiﬁcant increases in CTx were observed in PTH males at D7 and
D57 (Fig. 2F). Absolute values for serum biomarkers are provided in
Supplemental Table 1.
3.2. Comparative effects of Scl-Ab and PTH on bone mass
Ex vivo pQCT analyses of L3 and the distal femurmetaphysis demon-
strated increased bonemass in Scl-Ab andPTHgroups after 26weeks, as
Fig. 1. (A) RUNX2-immunostained section of L6 vertebra illustrating the subpopulations of the osteoblast lineage targeted for number estimation. (B) Nestin-immunostained section of L6
vertebra illustrating the morphology and location of immunopositive marrow stromal cell.
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dependent increases in total vBMC, with 50 mg/kg Scl-Ab affecting the
greatest increases at both sites, to levels that were greater than thoseFig. 2. Time-dependent changes in serum bone turnover markers in female (A–C) and male (D
P1NP (B, E), and bone resorption marker CTx (C, F) were measured and expressed as a fold
shown as mean ± S.E.with PTH (Fig. 3A). The greater bonemass reﬂected increases in the tra-
becular compartment, with signiﬁcant gains in vBMD by pQCT and bone
volume (BV/TV) by histomorphometry (Fig. 3B–C). In males, the–F) rats treated with Scl-Ab or PTH. The bone formation markers osteocalcin (A, D) and
change relative to vehicle (Veh) controls. *p b 0.05 vs Veh, Pp b 0.05 vs PTH. Data are
Fig. 3. Effects of Scl-Ab (3 or 50mg/kg/week) and PTH (75 μg/kg/day) on trabecular (Tb.) and cortical (Ct.) bonemass and geometry in female rats treated for 26weeks. (A) Total vBMC and
(B) Tb. vBMDwere measured by pQCT at the L3 vertebral body and left distal femur, while (C) Tb. bone volume (BV/TV) was measured by histomorphometry at the L4 vertebra and the
right distal femur. (D) Ct. vBMC, (E) periosteal perimeter (Ps.Pm), and (F) endocortical perimeter (Ec.Pm)were alsomeasured by pQCT at the femoral diaphysis. *p b 0.05 vs vehicle (Veh),
Pp b 0.05 vs PTH. Data are shown as mean ± S.E.
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greatest increases in distal femur bone mass parameters were with
PTH treatment (Supplemental Table 2). Comparisonwith data collected
after 4 weeks of treatment demonstrate the expected age-dependent
increases in bone mass in Veh groups with more pronounced progres-
sive increases in Scl-Ab and PTH groups (Supplemental Table 3). Nota-
ble was a more rapid increase in bone mass in the distal femur in PTH
males at 4 weeks (Supplemental Table 2).
In females at week 26, femur diaphyseal cortical vBMC was signiﬁ-
cantly increased by11% and 53% in the PTHand50mg/kg Scl-Ab groups,
respectively (Fig. 3D). The gains in cortical bone mass were associated
with similar reductions in endocortical (Ec.) perimeter in both groups,
while only 50 mg/kg Scl-Ab signiﬁcantly increased periosteal (Ps.) pe-
rimeter (Fig. 3E–F and Supplemental Table 3). Similar improvements
in cortical bone parameters were found in males treated with Scl-Ab
and PTH for 26 weeks, though the increases in vBMCwere more similar
in magnitude (Supplemental Table 2).3.3. Comparative histopathology of Scl-Ab and PTH
Qualitative evaluation of tibia, humerus, and vertebrae from males
and females at 4 and 26 weeks revealed a minimal increase in
peritrabecular stromal cells in PTH-treated rats in the proximal
metaphysis of tibia (seven of 10 males) and humerus (three of
10 males; three of 10 females) at 4 weeks, which was not present at
26 weeks (Supplemental Fig. 1). These cells likely represent
osteoprogenitors as previously characterized [22]. The increase in
peritrabecular stromal cells at 4 weeks may correlate with the more
rapid increase in metaphyseal trabecular bone in PTH-treated males.
Rare foci of woven bone were observed at a low incidence in the long
bone in PTH-treated females at 4 and 26 weeks, typically in the epiphy-
seal cancellous bone or in the distal metaphysis (Supplemental Fig. 2).
In both PTH and Scl-Ab-treated rats, Ob hyperplasia was not observed
and Ob morphology varied as expected, dependent upon the age of
the associated formative surface.3.4. Comparative effects of Scl-Ab and PTH on bone histomorphometry
Consistent with the increases in serum biomarkers and trabecular
and cortical bonemass, both Scl-Ab and PTH resulted in increases in his-
tological bone formation parameters in L4, distal femurmetaphysis, and
femur diaphysis. As these effects were generally similar across sexes,
the data from female rats are presented in Figs. 4 and 5 and Supplemen-
tal Table 4, while male data are provided in Supplemental Table 5.
In L4 and distal femur cancellous bone, marked signiﬁcant increases
in mineralizing surface (MS/BS), mineral apposition rate (MAR), and
bone formation rate (BFR/BS) were observed at week 4 with 50 mg/kg
Scl-Ab. These parameters decreased in all treatment groups with
age but remained signiﬁcantly increased with 50 mg/kg Scl-Ab relative
to Veh at week 26. For BFR/BS at L4, the Scl-Ab-mediated increases in
BFR/BS attenuated from 12-fold to 3-fold and from 6.3-fold to 0.6-fold,
from week 4 to 26 in female and male rats, respectively, relative
to Veh (Table 1). This relative attenuationwas not observed at the distal
femur. PTH also signiﬁcantly increased these parameters at week 4,
to levels that were generally lower than values at 50 mg/kg Scl-Ab, ex-
cept for the male distal femur where PTH had the greater effects (Sup-
plemental Table 5). At week 26 in L4, PTH resulted in a 3.4 fold
increase in BFR/BS fromVeh in females,with BFR/BS inmales essentially
at Veh values (Table 1). Consistent with the observed increases in
cancellous BV/TV, bone formation was increased with 3 mg/kg Scl-Ab
at these sites but to a lesser degree than that with 50 mg/kg Scl-Ab.
At the distal femur, signiﬁcant increases were observed for MS/BS
and BFR/BS in both sexes and at both timepoints with 3 mg/kg Scl-Ab
relative to Veh, while signiﬁcant increases in these parameters in L4
were only observed at week 4 in males (Fig. 4 and Supplemental
Table 5).
Effects on trabecular bone resorption were limited to modest signif-
icant increases in osteoclast surface (Oc.S/BS) with PTH at weeks 4 and
26 in L4 in both sexes relative to Veh, and amodest signiﬁcant decrease
with PTHat the distal femur inmales atweek4 (Fig. 4D and Supplemen-
tal Tables 4 and 5). Across all groups and sites, there was an age-
dependent decrease in Oc.S/BS from week 4 to 26.
Fig. 4. Effects of Scl-Ab (3 or 50mg/kg/week) and PTH (75 μg/kg/day) on trabecular (Tb.) histomorphometric parameters in female rats treated for 4 or 26weeks. (A)Mineralizing surface
(MS/BS), (B)mineral apposition rate (MAR), (C) bone formation rate (BFR/BS), and (D) osteoclastic surface (Oc.S/BS)weremeasured in the L4 vertebral body and distal femur. *p b 0.05 vs
vehicle (Veh), Pp b 0.05 vs PTH, Tp b 0.05 week 4 vs week 26. Data are shown as mean ± S.E.
Fig. 5. Effects of Scl-Ab (3 or 50mg/kg/week) and PTH (75 μg/kg/day) on cortical histomorphometric parameters in female rats treated for 4 or 26weeks. Percent labeled perimeter (L.Pm),
mineral apposition rate (MAR), and bone formation rate (BFR/BS) were measured on the periosteal (Ps.) (A–C) and endocortical (Ec.) (D–F) surfaces of the femur diaphysis. *p b 0.05 vs
vehicle (Veh), Pp b 0.05 vs PTH, Tp b 0.05 week 4 vs week 26. Data are shown as mean ± S.E.
385M.S. Ominsky et al. / Bone 81 (2015) 380–391
Table 1
Fold-change from vehicle for L4 and distal femur trabecular bone formation rate, and femoral diaphyseal periosteal and endocortical bone formation rate of femoral bone in male and fe-
male rats treated with Scl-Ab or PTH for 4 and 26 weeks.
Female rats Male rats
Scl-Ab
(50 mg/kg/week)
PTH
(75 μg/kg/day)
Scl-Ab
(50 mg/kg/week)
PTH
(75 μg/kg/day)
Week 4 Week 26 Week 4 Week 26 Week 4 Week 26 Week 4 Week 26
L4 Tb.BFR/BS 11.90 2.94 3.14 3.40 6.27 0.59 1.89 1.08
DF Tb.BFR/BS 5.62 7.45 3.21 5.94 1.26 3.57 1.20 1.48
FD Ps.BFR/BS 4.28 0.24 0.68 −0.32 0.94 0.16 0.03 0.08
FD Ec.BFR/BS −0.28 32.23 0.14 1.80 −0.18 82.45 −0.02 21.39
Data are shown as fold change from vehicle. Abbreviations: DF=distal femur, Ec.BFR/BS=endocortical bone formation rate, FD= femoral diaphysis, L4= lumbar vertebra 4, Ps.BFR/BS=
periosteal bone formation rate, PTH = parathyroid hormone, Scl-Ab = sclerostin antibody, Tb.BFR/BS = trabecular bone formation rate.
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periosteal labeled perimeter (Ps.L.Pm) and Ps.BFR/BS at week 4 with
sustained increases in Ps.L.Pm evident at week 26 in females. Ps.BFR/
BS at week 26 was similar to Veh due to the signiﬁcant age-related de-
crease in Ps.MAR, evident in all treatment groups (Fig. 5A–C). At the
endocortical surface, Ec.MAR and Ec.BFR/BS in females treated with
50 mg/kg Scl-Ab was signiﬁcantly lower than PTH at week 4, however
at week 26, Ec.BFR/BS was increased compared with Veh- and PTH-
treated females (Fig. 5D–F and Supplemental Table 3). Signiﬁcant in-
creases in endocortical labeled perimeter (Ec.L.Pm) and Ec.MAR accom-
panied the increased Ec.BFR/BS (Fig. 5D–F). A majority of cortical
samples in the Veh groups at week 26 did not contain double labels
on the endocortex, thus an imputed value of 0.3 μm was used for
Ec.MAR. The cortical effects with 3 mg/kg Scl-Ab were limited to signif-
icant increases in Ec.L.Pm and Ec.MAR atweek 26 inmales (Supplemen-
tal Tables 4 and 5).
Although neither Scl-Ab nor PTH affected longitudinal growth rate
(LGR) at the distal femoralmetaphysis at week 4 or 26, PTH signiﬁcantly
increased femoral bone length at 26 weeks. Time-dependent effects on
bone length and LGR were observed in all groups as a consequence of
aging (Supplemental Table 6).Fig. 6. (A–E)Osteoblast stereological estimates and correlationswith (F–G)mineralizing surface
rats treated with Scl-Ab (3 or 50 mg/kg/week) or PTH (75 μg/kg/day) for 4 and 26 weeks. Abb
density, Ob.Fp = osteoblast footprint; Ob.S*MAR/Ob.N = osteoblast vigor. *p b 0.05 vs vehicl
Methods, with the exception of Ob.S*MAR/Ob.N which was performed as 2-way ANOVA + T
mean ± S.E.3.5. Comparative 3-D quantitative changes in the Ob lineage: stereological
analyses of lumbar vertebrae from female rats
3.5.1. Effects on Ob
To assess the accuracy and consistency of classiﬁcation of RUNX2-
immunopositive bone surface cells as active Ob for total osteoblastic
surface (Ob.S) and total Ob number (Ob.N) estimation, linear regression
of %Ob.S (Ob.S/BS) derived from 3D estimates vs 2-D MS/BS was per-
formed; positive linear correlations were evident at weeks 4 (overall
r2 = 0.93, p b 0.0001) and 26 (overall r2 = 0.85, p b 0.0001) (Supple-
mental Fig. 3). MS/BS was slightly but consistently lower than Ob.S/BS
at both timepoints across all groups, which may reﬂect differences be-
tween a 2-D and 3-D estimate, the regions of interest, or the timing of
bone formation.
Ob.S was increased in the 50 mg/kg Scl-Ab and PTH groups at
both weeks 4 and 26, consistent with 2-D surface-referent dynamic
parameters (Fig. 6A). Ob.Swas signiﬁcantly attenuated atweek 26 com-
pared with week 4 in Veh and Scl-Ab at 50 mg/kg. Corresponding in-
creases in Ob.N were observed in the 50 mg/kg Scl-Ab and PTH groups
at both timepoints but were signiﬁcantly attenuated at week 26 with
50mg/kg Scl-Ab compared with week 4 (Fig. 6B). The lack of signiﬁcant(MS/BS) and (H–I)mineral apposition rate (MAR) obtained fromL6 vertebrae from female
reviations: Ob.S = osteoblast surface, Ob.N= osteoblast number, Ob.N/Ob.S = osteoblast
e (Veh), Pp b 0.05 vs PTH, Tp b 0.05 week 4 vs week 26. All analyses were performed per
ukey's post hoc test within Prism. All regressions (F–I) were p b 0.01. Data are shown as
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with more constant sustained bone formation, more evident with the
sensitive 3D estimates. In the Veh and 3 mg/kg Scl-Ab groups, Ob.S sig-
niﬁcantly decreased with age from week 4 to 26, with Ob.N sustained
over the same period.
To assess the relative effects of Scl-Ab and PTH on the number of Ob
contributing to bone formation on active formative sites, Ob density
(Ob.N/Ob.S; the number of Ob per unit of Ob.S) and its inverse,
Ob footprint (Ob.Fp; the amount of Ob.S interfaced with an in-
dividual Ob), were calculated (Fig. 6C–D). From week 4 to 26 in the
Veh and 3 mg/kg Scl-Ab groups, Ob.N/Ob.S increased, resulting in a de-
crease in Ob.Fp. Although no effect of 50 mg/kg Scl-Ab or PTH on these
parameters was observed at week 4, signiﬁcantly lower Ob.N/Ob.S and
greater Ob.Fp were observed at week 26 with both agents, compared
to Veh. These week 26 indices were generally maintained at levels sim-
ilar to those in all groups at week 4, although the decrease in Ob.N/BS
with 50 mg/kg Scl-Ab exceeded that of PTH, resulting in relatively
lower Ob.N/Ob.S and greater footprint on a formative surface.
Linear regression analysis revealed a time-dependent change in the
relationship of Ob.N/BS and MS/BS, both referent to total bone surface
(BS). As expected, a positive correlation of Ob.N/BS and MS/BS was ob-
served at week 4 (overall r2 = 0.63, p b 0.0001), with Veh and 3 mg/kg
Scl-Ab clustered at lower Ob.N/BS and MS/BS values, PTH intermediate
in values, and 50 mg/kg Scl-Ab at the upper end of the regression
(Fig. 6F). Although the correlation remained positive across groups at
week 26, it was weaker (overall r2 = 0.24, p = 0.001), with the slope
of the regression line shifted lower and the distribution of the groups
changed (Fig. 6G). Ob.N/BS values for 50 mg/kg Scl-Ab were similar to
those for Veh at week 26, despite MS/BS values that were higher and
maintained in the range of PTH. Interestingly, although the data ob-
served with Veh and 3 mg/kg Scl-Ab treatment remained clustered at
the low end of the regression at week 26, MS/BS values decreased rela-
tive toweek 4, while Ob.N/BS values remained in theweek 4 range, sug-
gesting a decline in Ob function with age.
The observation that 50 mg/kg Scl-Ab effectively maintained MS/BS
values equivalent to PTH with lower Ob.N suggested that Scl-Ab in-
creased activity at the level of the individual Ob (ie, enhanced Ob
vigor to maintain bone formation with fewer Ob). Regression analysis
of Ob.Fp, the amount of active forming bone surface “serviced” by an in-
dividual Ob, and MAR demonstrated a positive correlation at weeks 4
(Fig. 6H) and 26 (Fig. 6I). At week 4, although all groups spanned a rel-
atively comparable range of Ob.Fp values, the highest MAR values were
associated with 50 mg/kg Scl-Ab. At week 26, Ob.Fp values were mark-
edly shifted towards the higher values with 50 mg/kg Scl-Ab, with sim-
ilar or slightly higher MAR values as the other groups. Although MAR
provides a traditional histological assessment of Ob vigor, a new vigor
index (Ob.S*MAR/Ob.N) was calculated using the stereological data to
reﬂect the total bone formed per Ob. Ob.S*MAR/Ob.N was signiﬁcantly
increased at both timepoints in the 50 mg/kg Scl-Ab relative to Veh
and PTH, and was shown to decline with age across all groups
(Fig. 6E). Together, these data indicated that Scl-Ab had a greater effect
on Ob vigor compared with PTH.
3.5.2. Effects on osteoprogenitor populations
Three separate populations of osteoprogenitors were quantiﬁed to
assess the effects of treatment and time on the Ob lineage at multiple
stages. Total peritrabecular osteoprogenitor number (PTb.Op.N) repre-
sented themostmature osteoprogenitor adjacent to Ob, whilemore im-
mature osteoprogenitors located in the marrow were characterized as
Ma.Op and Ma.St.Ce. At week 4, no signiﬁcant treatment effects were
observed on these three osteoprogenitor populations (Fig. 7A–C). At
week 26, PTb.Op.N and number of Ma.Op (Ma.Op.N) were dose-
dependently reduced in the Scl-Ab groups relative to Veh,while PTH re-
duced Ma.Op.N but not PTb.Op.N. With 50 mg/kg Scl-Ab, the decreases
in PTb.Op.N and Ma.Op.N from week 4 to 26 were signiﬁcant, resulting
in a mean value that was signiﬁcantly lower than the PTH group. Thetemporal decreases with Scl-Ab contrasted to the increases in these
osteoprogenitors observed with aging in Veh. The number of Ma.St.Ce
(Ma.St.Ce.N) was not signiﬁcantly changed by Scl-Ab or PTH at week
26 relative to Veh, although 50 mg/kg Scl-Ab resulted in a signiﬁcantly
lower mean value relative to PTH. Time-dependent decreases in
Ma.St.Ce.N were observed in the Veh and Scl-Ab groups that achieved
signiﬁcance at 3 mg/kg Scl-Ab. Overall, these data suggest that Scl-Ab
effected reductions in all three osteoprogenitor pools with chronic
treatment relative to Veh and/or PTH.
Because the osteoprogenitor populations support the demands
for Ob, the relationship of each osteoprogenitor population number
to Ob.N was examined. Across all treatment groups, PTb.Op.N was
signiﬁcantly correlated with Ob.N at weeks 4 (r2 = 0.63, p b 0.0001)
and 26 (r2=0.51, p b 0.0001; Fig. 7D). Similarly,Ma.Op.Nwas positively
correlated toOb.N atweeks 4 (r2=0.24, p=0.0015) and 26 (r2=0.15,
p = 0.013; Fig. 7E). Individual group regression lines were similar for
these relationships at week 4; however, at week 26 the Veh data were
shifted higher, reﬂecting greater numbers of osteoprogenitors relative
to Ob. Presumably the earliest progenitor, Ma.St.Ce.N, only signiﬁcantly
correlated with Ob.N at week 26 (r2 = 0.44, p b 0.001; Fig. 7F) and
showed a similar relationship across groups. The inverse of the regres-
sion line slope reﬂects the ratio of Ob to progenitor cells at each stage.
At week 26, there were approximately two, three, and 25 Ob for every
one PTb.Op, Ma.Op, and Ma.St.Ce, respectively. Additionally, at week
26, there was a positive correlation between the progenitor populations
(Supplemental Fig. 4). Overall, the data suggest that progenitor cell pop-
ulation numbers are in a coordinated dynamic relationshipwith one an-
other to meet the requirements for Ob demands on the bone surface.
BS and marrow volume (Ma.V) may have inﬂuenced the total num-
ber of osteoprogenitors, as both of these were affected by time and
treatment (Supplemental Fig. 5). Therefore, PTb.Op.N were normalized
to BS and the marrow progenitors (Ma.Op.N andMa.St.Ce.N) were nor-
malized toMa.V for further evaluation (Fig. 7G–I). These normalized cell
densities were generally consistent with the total numbers, reﬂecting
dose-dependent decreases in PTb.Op.N/BS and Ma.Op.N/Ma.V with
Scl-Ab at week 26, while PTH did not change these parameters. At
week 4, PTb.Op.N/BS and Ma.Op.N/Ma.V were signiﬁcantly increased
in the 50 mg/kg Scl-Ab and PTH groups. These normalized results sug-
gest that the early response to Scl-Ab and PTH was to increase these
progenitors to supply Ob to meet demands for the increase in Ob.S,
an effect which was reversed with Scl-Ab treatment over time.
Ma.St.Ce.N/Ma.V was reduced at week 26 in all groups except PTH,
with the time-dependent reduction signiﬁcant at 3 mg/kg.
3.5.3. Effects on L.Ce
The number of L.Ce (L.Ce.N) was decreased with 50 mg/kg Scl-Ab
and PTH at week 4, consistent with the robust increases in bone forma-
tion on trabecular surfaces at this timepoint. From week 4 to 26, Scl-Ab
at 3 and 50 mg/kg resulted in further decreases in L.Ce.N by 48% and
66%, respectively, while a signiﬁcant decrease over time was not ob-
served with PTH. At both timepoints, L.Ce.N was signiﬁcantly less with
50mg/kg Scl-Ab thanwith PTH (Fig. 8A). Normalization of L.Ce.N to qui-
escent bone surface (QS) reﬂected the L.Ce.N per surface (L.Ce.N/QS),
while its inverse, lining cell footprint (L.Ce.Fp), reﬂects the surface occu-
pied by each L.Ce. At week 4, L.Ce.Fp was decreased with 50 mg/kg Scl-
Ab, perhaps reﬂecting a retraction of L.Ce due to the highly osteogenic
state in this group and the extent of activation of modeling-based for-
mation. However, at week 26, L.Ce.Fp was increased relative to Veh by
1.4-fold and 2-fold with 3 and 50 mg/kg Scl-Ab, respectively, with
values with 50 mg/kg Scl-Ab signiﬁcantly different from PTH, which
was increased only modestly (Fig. 8B).
Because changes in L.Ce number and density could be a conse-
quence, at least in part, to changes in Ob.N/Ob.S, the linear correlation
of Ob.Fp with L.Ce.Fp was explored. There was no signiﬁcant correlation
atweek 4, but a signiﬁcant positive correlationwas observed atweek 26
(r2= 0.33, p b 0.0001), with the strongest individual group correlations
Fig. 7. Stereological estimates of total number of (A) peritrabecular osteoprogenitor (PTb.Op.N), (B) marrow osteoprogenitor (Ma.Op.N), and (C) marrow stromal cells (Ma.St.Ce.N), and
(D–F) respective correlationswith total osteoblast number (Ob.N) obtained from L6 vertebrae from female rats treatedwith Scl-Ab (3 or 50mg/kg/week) or PTH (75 μg/kg/day) for 4 and
26weeks. (G–I)Normalization of osteoprogenitor numbers for bone surface (BS) andmarrowvolume (Ma.V). *p b 0.05 vs vehicle (Veh), Pp b 0.05 vs PTH, Tp b 0.05week 4 vsweek 26. Data
are shown as mean ± S.E.
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Ab, r2 = 0.56) (Fig. 8C–D). These data suggest that potentially progres-
sive reductions in Ob.N/Ob.S changes at the active bone formation sites
contribute to reduced L.Ce density in response to Scl-Ab.
4. Discussion
The present study aimed to investigate the comparative quantitative
effects of two bone forming agents, Scl-Ab and PTH, on bone at the
organ, tissue, and cellular levels; speciﬁcally, at the level of the Ob line-
age, in adolescent male and female rats. The ﬁndings illustrate that at
high pharmacologic doses, the two agents display differences at
26 weeks of dosing. The highest doses used in this study were those
used in the respective rat lifetime studies (Amgen, data on ﬁle) [23].
The discussion regarding comparison of these agents will focus primar-
ily on these two dose groups.
The densitometric, histomorphometric, and bone biomarker ﬁnd-
ings in this studywere not unanticipated, based on studies that have ex-
amined effects of these agents in studies in rats with Scl-Ab [14] and
PTH analogs [24,25]. Both agents increased cancellousmass in the distal
femur and vertebrae but with some differences. Compared with PTH,
Scl-Ab had comparatively greater effects on bone mass in the spine
and distal femur as a consequence of higher cancellous BFR/BS at
week 4 and, unlike PTH, occurred in the absence of increased Oc.S/BS
at both timepoints. Both agents increased cortical bone mass, with ef-
fects of PTH limited to a relative increase in Ec.BFR/BS compared withScl-Ab at week 4. Scl-Ab effected more rapid increases in cortical bone
mass and elicited larger increases due to effects on both periosteal and
endocortical surfaces. The pattern of effects on bone resorption and for-
mation markers reﬂected tissue-based histomorphometric indices and
the differences in the modes of bone formation between these two
agents. The biomarker data illustrated the more pronounced attenua-
tion of bone formation with Scl-Ab over time, which was reﬂected in a
greater attenuation of L4 BFR/BS relative to Veh and PTH. Interestingly,
although decreases in bone formation parameters were observed at the
distal femurmetaphysis and femur endocortexwith aging, the increases
with 50 mg/kg Scl-Ab relative to Veh did not attenuate. The results are
consistent with previous reports in ovariectomized rats treated for up
to 26 weeks [14] and may suggest that the temporal effects of Scl-Ab
on bone formation are site-speciﬁc. In contrast, the bone forming effects
of PTH did not attenuate signiﬁcantly relative to Veh fromweek 4 to 26.
Themore pronounced attenuation of bone formation, evident in the
biomarkers and L4 histomorphometric data with chronic Scl-Ab treat-
ment, was associated with quantitative differences in subpopulations
of the Ob lineage comparedwith PTH that was revealed by stereological
analyses. Although Ob.N increased at week 4 with both agents, Ob.N/
Ob.S remained similar to Veh. However, at week 26, both PTH and Scl-
Ab had reduced Ob.N/Ob.S compared to Veh, maintaining values closer
to that of younger rats. These effects were more pronounced with Scl-
Ab, which had signiﬁcantly lower total Ob.N, lower Ob.N/Ob.S, and
greater Ob.Fp compared with PTH despite similar MS/BS. The differ-
ences inOb.N/Ob.S between PTH and Scl-Abmay reﬂect different effects
Fig. 8. (A–B) Lining cell stereological estimates and (C–D) correlationswith osteoblast footprint (Ob.Fp) obtained fromL6 vertebrae from female rats treatedwith Scl-Ab (3 or 50mg/kg/week)
or PTH (75 μg/kg/day) for 4 and 26weeks. Abbreviations: L.Ce.N= lining cell number, L.Ce.Fp= lining cell footprint. *p b 0.05 vs vehicle (Veh), Pp b 0.05 vs PTH, Tp b 0.05week 4 vsweek 26.
Data are shown as mean ± S.E.
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the formative site. PTH has been demonstrated to inhibit Ob apoptosis
in vivo [26], an effect that could increase Ob.N/Ob.S. The effect of Scl-
Ab on Ob lifespan in vivo is unknown. An increase in Ob apoptosis
could contribute to the decreased Ob.N/Ob.S with chronic Scl-Ab
administration, although this would not be consistent with reports
that sclerostin promotes apoptosis in human Ob cells [27] and
that decreased Ob apoptosis has been observed in transgenic mice ex-
pressing the Wnt-activating LPR5 mutation [28]. The increases in MAR
with Scl-Ab could effect greater incorporation of Ob into bone matrix
as osteocytes, which could contribute to the observed decrease in
Ob.N/Ob.S.
Differential effects onOb.N/Ob.Smay also be due to differences in re-
cruitment of progenitors to the formative surface, with osteoprogenitor
numbers reﬂecting those demands. Therewere positive correlations be-
tween total numbers of osteoprogenitor subpopulations with Ob.N as
well as positive correlations among the progenitor populations. These
results suggest that these progenitor cells are dynamically coordinated
with one another to meet the demands and/or control the delivery of
Ob to the bone surface. Although Ob and progenitor number were cor-
related, it is unclear which cell population is potentially driving changes
in the other, or if the osteocyte is playing a role as a key regulator of the
Ob and progenitor pools. When normalized for changes in bone surface
area andmarrow volume, RUNX2+progenitors initially increasedwith
both PTH and 50mg/kg Scl-Ab. With chronic treatment, Scl-Ab resulted
in a signiﬁcant decrease in the progenitors despite maintaining bone
formation that was similar to PTH. Both PTH and Scl-Ab have been re-
ported to increase the number of osteoprogenitors in vivo in rodents
[29–31] following a fewweeks of treatment; however, the long-termef-
fects of these agents on osteoprogenitor number in vivo have not been
reported previously.The mechanism for the signiﬁcant down-regulation of progenitor
number with Scl-Ab is unknown but likely contributed to the attenua-
tion of bone forming effects in the lumbar spine. Nioi et al. [2] reported
that Scl-Ab administration in rats resulted in gene expression changes
that were consistent with cell cycle arrest in the mature Ob lineage by
microarray after 1 week. If this expression pattern translates to the ear-
lier progenitors with extended Scl-Ab dosing, this signature could ex-
plain the reduction in progenitor number. Gene expression changes
related to the cell cycle have also been reported for PTH, although pro-
and anti-proliferative effects appear to cycle daily with each injection
[32]. The difference in the response of the progenitor pools to chronic
treatment with Scl-Ab and PTHmay be a reﬂection of these differences
in gene expression; however, further longer-term transcriptional stud-
ies are needed. In addition, the use of other models, such as engineered
mice, for lineage tracing would allow for more speciﬁc progenitor iden-
tiﬁcation, quantiﬁcation, isolation, and proﬁling to better understand
the molecular mechanism mediating the changes in progenitor pools.
The analyses of the progenitor populations in this studywere limited
due to the availability of phenotypic markers for the Ob lineage in the
rat and were restricted to populations that expressed RUNX2 or nestin.
RUNX2 was used as a lineage marker based on its known role in osteo-
blastogenesis and its expression from osteoprogenitor to mature Ob to
L.Ce. Nestinwas used based on its description as amarker of themesen-
chymal stem cells (MSC) [33]; however, recent lineage tracing data in
mice indicates that in developing bone, nestin marks a progenitor pool
of both theOb and endothelial cell lineage [34]. Therefore, it is an imper-
fect marker of the MSC. An additional limitation was that proliferation
was not assessed in the progenitor populations, which would have
allowed insight into the cell kinetics of these progenitors. Unfortunately,
the lack of phenotypic markers for the progenitors that could be com-
bined with nuclear proliferation markers precluded this assessment.
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PTH treatment, differential functional effects at the individual Ob level
were observed at both timepoints. At week 4, MAR was increased to a
greater extent with Scl-Ab than with PTH or Veh, despite similar
Ob.Fp. At week 26, Scl-Ab maintained MAR at similar or higher values
than PTH in the face of a signiﬁcantly larger Ob.Fp. These parameters
were combined to form a stereological index of individual Ob vigor
(Ob.S*MAR/Ob.N) that was signiﬁcantly increased by Scl-Ab relative to
PTH at both timepoints. Together, these data indicate that early in the
course of treatment, Ob.N/Ob.S on a formative site is not affected by
PTH or Scl-Ab, but Scl-Ab has a greater effect on the individual activity
of the Ob. With chronic treatment, bone formation is maintained by
Scl-Ab with lower Ob.N/Ob.S by maintaining increased Ob activity or
vigor. Gene expression data from laser capture microdissection-
enriched samples of Ob isolated from Scl-Ab–treated rat vertebrae sup-
ports an increase in Ob vigor, as reﬂected in signiﬁcant increases in Ob
functional genes as early as 6 h[2].
The last cell of the Ob lineage subjected to quantiﬁcation was the
L.Ce that showed signiﬁcant reduction in density and increased foot-
print at week 26 with Scl-Ab. This reduction may reﬂect an integration
of changes in Ob.N/Ob.S that would have affected a large percentage
of the bone surface across the treatment period. In contrast, the early
decrease in L.Ce.Fp with Scl-Ab may have reﬂected L.Ce contraction in
response to the dramatic increase in Ob.S.
The 3 mg/kg Scl-Ab-treated groups displayed several of the changes
observed at 50mg/kg butmoremodest in effect in one or both genders.
These included early transient increases in bone formationmarkers that
were associated with increased BFR/BS, resulting in increases in bone
mass primarily in trabecular bone. Quantitative changes in the Ob sub-
populations at week 26 included reduction in PTb.Op, Ma.Op, Ma.St.Ce,
and PTb.Op/BS as well as increased L.Ce.Fp. Notably, the signiﬁcant in-
crease in L.Ce.Fp at 3 mg/kg occurred in the absence of detectable in-
creases in Ob.Fp. Effects on Ob.N/Ob.S and footprint at this dose may
have been subtle and below the sensitivity of the methods employed
but may have been reﬂected in changes in L.Ce.Fp that would integrate
changes in Ob.N/Ob.S over the timecourse. As discussed previously, it is
possible that other mechanismsmay be involved that affected L.Ce.N in
response to Scl-Ab, such as apoptosis. Further studieswould be required
to investigate the mechanism of increased L.Ce.Fp.
There were changes in Ob subpopulations related to aging that were
noteworthy. Ob.N/Ob.S displayed time-dependent increases, with re-
ciprocal decreases in Ob.Fp, and increases in progenitor populations.
These data suggest that with aging, Ob lose activity or vigor and require
a higher density with smaller footprint to maintain MAR; this is
reﬂected in a reduction in the vigor index Ob.S*MAR/Ob.N and results
in a greater number of progenitors required to service formative sites.
In contrast, L.Ce.N and L.Ce.Fp were maintained with age, suggesting
that aging results in a decrease in Ob lifespan to maintain cell density
on quiescent surfaces.
Neither Scl-Ab nor PTH increased longitudinal bone growth rate in
these growing rats after 4 or 26 weeks, although PTH resulted in in-
creased femur length in both sexes. These increases are consistent
with previous reports of approximately 5% increases in femur length
after long-term PTH treatment in similarly aged rats [23], an effect
that has been associated with increased growth plate length [35]. Al-
though genetic ablation of sclerostin has been associatedwith increased
stature in patients with sclerosteosis [36], only a minor increase in
femur length was reported in female, but not male, SOST-KOmice [37].
The present study employed robust stereological methods which, to
date, have not been used to investigate quantitative changes in cell
number in bone. These sensitivemethods revealed that Scl-Ab can effect
increases in cancellous bone mass with the same or fewer numbers of
Ob by increasing Ob.Fp and increasing Ob activity or vigor compared
with PTH. This reduction in density of Ob on the formative site was as-
sociated with a coordinated reduction in osteoprogenitors that was
more pronounced than the effects with PTH. These time-dependentreductions in subpopulations of the Ob lineage may be integral to the
greater attenuation or self-regulation of bone formation observed at
the vertebra with Scl-Ab. PTH required more Ob at the formative site
with correlative increased numbers of progenitors compared with Scl-
Ab, indicating potentially greater stimulus for progenitor pool prolifera-
tion or differentiation.
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